Johnson & Johnson suspends sales forecast for COVID vaccines citing supply surplus, demand uncertainty
Johnson & Johnson announced on Tuesday it would be suspending its COVID-19 vaccine sales forecast, citing demand uncertainty and a global supply surplus.
The drug manufacturer, which made the announcement while reporting on its first quarter earnings results for 2022, reported $23.4 billion for its first quarter, compared to $22.3 billion around the same time last year.
However, it was lower than the projection of $23.6 billion that Refinitiv forecasted, according to Reuters.
Adjusted earnings per share was at $2.67, which Reuters noted was higher than the $2.56 per share that was expected.
Johnson & Johnson noted that its COVID-19 vaccine sales helped contribute to company growth but said that its declining sales of Remicade, an inflammatory disease treatment, partially offset those gains.
Still, the COVID-19 vaccine brought in much less than what the drugmaker had anticipated: $457 million in the first quarter compared to estimates of as much as $3.5 billion, Reuters noted, due to safety concerns and low demand.
Late last year, the Centers for Disease Control and Prevention (CDC), citing a higher risk of blood clotting for young and middle-aged women, said that the Pfizer and Moderna COVID-19 vaccines should be recommended by health providers over the Johnson & Johnson vaccine.
The recommendation by the CDC does not limit the Johnson & Johnson vaccine itself.
Research has also shown that two doses of the mRNA vaccines — Pfizer and Moderna — are more effective against COVID-19 than one shot of the Johnson & Johnson vaccine, and the CDC has since recommended a booster shot two months after people have gotten their initial Johnson & Johnson vaccine.
The Hill has removed its comment section, as there are many other forums for readers to participate in the conversation. We invite you to join the discussion on Facebook and Twitter.